FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 600 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR The ‘major conditions strategy’: will ministers fail to give cancer the... February 6, 2023 Olivia Newton-John Puts On Iconic ‘Grease’ Costume And Talks About Cancer... October 3, 2019 Longer Duration of Treatment with ICIs Associated with a Higher Rate... March 5, 2025 FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... November 16, 2020 Load more HOT NEWS Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line... The Benefits of Yoga During Cancer and How to Get Started Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical...
